Home' Australian Pharmacist : Australian Pharmacist September 2015 Contents Australian Pharmacist September 2015 I ©Pharmaceutical Society of Australia Ltd.
Continuing Professional DeveloPment
Australian Pharmacist Continuing professional
development (Cpd) is a central element of psa’s
Cpd & pi program.
the Cpd section is recognised under the psa
Cpd & pi program as a group 2 activity. members
can choose which articles they want to answer
questions on and get Cpd credits based on the
questions they answer.
Cpd credits are allocated based on the length of
the article and the complexity of the information
presented. a minimum of 6 out of 8 questions, 4 out
of 5 questions, or 3 out of 4 questions correct is
required for the allocation of group 2 Cpd credits.
psa members can answer online at www.psa.org.au.
• login to submit your answers online. if you
do not have member access details, you can
request them via a link from the login page.
• select submit answers.
• select Australian Pharmacist Cpd.
Submit your answers online before
1 November 2017 at www.psa.org.au
and receive automatic feedback.
1. which one of the following tests
is used to screen for depression in
people with dementia?
a) mini mental state examination (mmse).
b) Cornell scale for depression in
c) behaviour rating scale for dementia
d) hierarchic dementia scales - revised
2. which one of the following
statements regarding wandering is
the most appropriate?
a) wandering is rarely observed in people
b) wandering is synonymous with non-
c) wandering may be precipitated by
d) wandering is generally straightforward
to manage with antipsychotics.
3. By which one of the following
mechanisms is dothiepin least likely
to cause or exacerbate wandering?
a) antidepressant effect.
b) Central anticholinergic effects.
c) induction of constipation.
d) sedative activity.
4. which one of the following
laboratory tests is least useful for
deficiency in a person
with clinical signs of deficiency?
a) active b12
c) mean corpuscle volume (mCV).
d) serum b12
5. a 78-year-old with advanced
dementia is admitted to an
rcf because his family can no
longer manage his incessant
wandering. which one of the
following statements regarding
his management is the least
a) his weight should be monitored to
ensure he is adequately nourished.
b) his risk factors for falls should be
identified and managed.
c) his medicines should be reviewed to
identify potential drug-induced causes
d) he should be physically restrained to
prevent disturbance to other residents.
1. folstein mf, folstein se, mchugh pr. mini-mental state. a
practical method for grading the cognitive state of patients
for the clinician. J psychiatr res 1975;12(3):189–98 .
2. alexopoulos gs, abrams rC, young rC, et al. Cornell scale for
depression in dementia. biol psychiatry 1988;23(3):271–84.
3. Cipriani g, lucetti C, nuti a, et al. wandering and dementia.
4. burns K, Jayasinha r, tsang r, et al. behaviour management
- a guide to good practice. sydney: university of new south
5. alagiakrishnan K, wiens Ca. an approach to drug induced
delirium in the elderly. postgraduate medical Journal
6. stabler sp. Vitamin b12 deficiency. n engl J med
7. nexo e, hoffmann-lücke e. holotranscobalamin, a marker
of vitamin b-12 status: analytical aspects and clinical utility.
am J Clin nutr 2011;94(1):359s–65s.
There are many ways by which
medications may influence the
behavioural and psychological
symptoms of dementia (BPSD),
and optimising medicine management
for any person with dementia requires
a comprehensive understanding of
both their medicines and medical
conditions. RMMRs for people with
dementia provide an opportunity to
comprehensively assess this important
aspect of their care, with the potential
to improve quality of life through
harm minimisation and optimisation
8. heidelbaugh JJ. proton pump inhibitors and risk of vitamin
and mineral deficiency: evidence and clinical implications.
ther adv drug saf 2013;4(3):125–33 .
9. rossi s, ed. australian medicines handbook. adelaide:
australian medicines handbook; 2015.
10. banerjee s, hellier J, dewey m, et al. sertraline or
mirtazapine for depression in dementia (hta-sadd): a
randomised, multicentre, double-blind, placebo-controlled
trial. the lancet 378(9789):403–11.
11. Kales hC, gitlin ln, lyketsos Cg. assessment and
management of behavioral and psychological symptoms
of dementia. bmJ 2015;350:h369.
Links Archive Australian Pharmacist August 2015 Australian Pharmacist October 2015 Navigation Previous Page Next Page